Skip to Content
Decentralized Clinical Trials-Web-banner

Are decentralized clinical trials the future?

In the last few years, there has been a dramatic increase in telemedicine, remote diagnoses, and prescribed treatment. The demand for these services highlighted their profound benefits, not only as a contingency but as a new modus operandi. But why stop at reactionary treatment?
Another consequence of the pandemic is the realization that we need to rethink the way we develop and deliver new drugs. Perhaps inspired by the rise of blockchain technology, the pharmaceutical industry has embraced the role of decentralization. As a result, many companies are now exploring the impact of Decentralized Clinical Trials (DCTs). New FDA guidance, increasing success of sponsorship, the removal of appointment conflicts, and streamlined data collection are just some of the major benefits.

Clinical trials are “pivotal” phases of drug development. Throughout the years, they’ve enabled patients across the world to access innovative therapies, advanced research, and medical knowledge.

Our Experts

Broderick Jones

Global Head of Life Science & Med Tech, Capgemini Invent
Broderick brings extensive Life Science and Healthcare experience to each client engagement with the goal of driving top-line growth and building capabilities for ongoing commercial success and cost management. His track record of developing high quality business strategies and transformation plans has driven unparalleled customer experience and internal operational excellence globally.

Damien Vossion

Vice President at Capgemini Invent, Life Sciences & Operating Model
I started my career as a consultant in 2000 and gained experience in major transformation projects in Manufacturing, Quality, Supply Chain, and clinical operations, with a strong focus on Industry 4.0 since 2015. I supported General Management in the Life Sciences sector (Pharmaceutical companies, Medical Device companies, and Chemical companies) as well as other large industrial and services companies. I now manage the Life Sciences department at Capgemini Invent in France and co-develop the Life Sciences in Switzerland.

Barnabé Lecouteux

Senior Director, Data & Analytics for Intelligent Industry, Capgemini Invent
Barnabé Lecouteux has 14 years of experience leading strategic and operational projects, with a focus on Data and Artificial Intelligence (AI) topics in the life sciences. He started his career as a consultant for Capgemini on operations transformation in the services, industry and life sciences sectors. Barnabé has a total of 8 years of experience in life sciences, first at Ipsen Pharma as Director of Strategic Planning and then at Air Liquide Healthcare, where he held the positions of Head of Chronic Renal Disease BU and Director of Digital Strategy for chronic diseases.

Salma Benchekroun

Pharm. D & ConsultantCapgemini Invent France